Biological
CoVAC-1
CoVAC-1 is a biological therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
completed267%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults
NCT05693272
completedphase_1
B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency
NCT04954469
withdrawnphase_1
A Clinical Trial of COVAC-1, a COVID-19 Vaccine, in Generally Healthy Adults
NCT05155982
Clinical Trials (3)
Showing 3 of 3 trials
NCT05693272Phase 1
A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults
NCT04954469Phase 1
B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency
NCT05155982Phase 1
A Clinical Trial of COVAC-1, a COVID-19 Vaccine, in Generally Healthy Adults
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3